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Human African trypanosomiasis, or sleeping sickness, is caused by the protozoan parasites Trypanosoma brucei rhodesiense or
Trypanosoma brucei gambiense, and is a major cause of systemic and neurological disability throughout sub-Saharan Africa.
Following early-stage disease, the trypanosomes cross the blood–brain barrier to invade the central nervous system leading to
the encephalitic, or late stage, infection. Treatment of human African trypanosomiasis currently relies on a limited number of
highly toxic drugs, but untreated, is invariably fatal. Melarsoprol, a trivalent arsenical, is the only drug that can be used to cure
both forms of the infection once the central nervous system has become involved, but unfortunately, this drug induces an
extremely severe post-treatment reactive encephalopathy (PTRE) in up to 10% of treated patients, half of whom die from this
complication. Since it is unlikely that any new and less toxic drug will be developed for treatment of human African trypano-
somiasis in the near future, increasing attention is now being focussed on the potential use of existing compounds, either alone
or in combination chemotherapy, for improved efﬁcacy and safety. The kynurenine pathway is the major pathway in the
metabolism of tryptophan. A number of the catabolites produced along this pathway show neurotoxic or neuroprotective
activities, and their role in the generation of central nervous system inﬂammation is well documented. In the current study,
Ro-61-8048, a high afﬁnity kynurenine-3-monooxygenase inhibitor, was used to determine the effect of manipulating the
kynurenine pathway in a highly reproducible mouse model of human African trypanosomiasis. It was found that Ro-61-8048
treatment had no signiﬁcant effect (P=0.4445) on the severity of the neuroinﬂammatory pathology in mice during the early
central nervous system stage of the disease when only a low level of inﬂammation was present. However, a signiﬁcant
(P=0.0284) reduction in the severity of the neuroinﬂammatory response was detected when the inhibitor was administered
in animals exhibiting the more severe, late central nervous system stage, of the infection. In vitro assays showed that Ro-61-
8048 had no direct effect on trypanosome proliferation suggesting that the anti-inﬂammatory action is due to a direct effect of
the inhibitor on the host cells and not a secondary response to parasite destruction. These ﬁndings demonstrate that kynurenine
pathway catabolites are involved in the generation of the more severe inﬂammatory reaction associated with the late central
nervous system stages of the disease and suggest that Ro-61-8048 or a similar drug may prove to be beneﬁcial in preventing or
ameliorating the PTRE when administered as an adjunct to conventional trypanocidal chemotherapy.
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Introduction
Human African trypanosomiasis (HAT), or sleeping sickness, is a
major threat to the health of 60 million people inhabiting
36 countries in sub-Saharan Africa (WHO, 1998). The disease is
caused by infection with the protozoan parasites Trypanosoma
brucei gambiense (T. b. gambiense)o rT. b. rhodesiense, causing
West African and East African sleeping sickness respectively
(Kennedy, 2004). Both forms of the disease are invariably fatal
if not effectively treated. HAT develops in two stages, the early,
or haemolymphatic, stage when the parasites multiply and spread
in the blood and lymph nodes, followed by the late, or encepha-
litic, stage when the parasites become established within the cen-
tral nervous system (CNS). Neurological features of late-stage HAT
include the characteristic sleep disorder with alteration of sleep
structure, a variety of neuropsychiatric symptoms, both motor
and sensory disturbances, and progressive cerebral oedema, incon-
tinence and coma leading to death (Kennedy, 2008) Early-stage
infections are treated with either pentamidine (for T. b. gambiense)
or suramin (for T. b. rhodesiense). However, the only drug that
is effective against both forms of the disease once the CNS
has become involved is the trivalent arsenical melarsoprol
(Kennedy, 2004). Unfortunately, melarsoprol is highly toxic and
treatment can result in the development of an extremely severe
post-treatment reactive encephalopathy (PTRE) in about 10% of
patients with a 50% mortality rate (Pepin and Milord, 1991,
1994). The PTRE is characterized neuropathologically by the
development of a meningoencephalitis with diffuse astrocytosis
and the presence of macrophages, lymphocytes and plasma cells
in cerebral white matter as well as perivascular cufﬁng (Adams
et al., 1986; Kennedy, 2006). Despite the unacceptable toxicity
of current drugs for late-stage HAT, it is highly unlikely that any
new and effective drugs will become available for use within the
next 5 years (Kennedy, 2008). Therefore, the prospects for
improved safety and efﬁcacy are more likely to come from
combination chemotherapy approaches utilizing contemporary
trypanocidal drugs with the inclusion of existing or newly devel-
oped compounds as adjuncts to help prevent the adverse side-
effects of the trypanocidal treatment.
One major metabolic pathway which has been little explored
in relation to trypanosomiasis is the oxidative conversion of tryp-
tophan to kynurenine compounds (Fig. 1). In most tissues
this pathway accounts for the majority of non-protein
tryptophan metabolism, and in the CNS several components of
the pathway have signiﬁcant effects on neuronal activity.
Quinolinic acid can activate a subpopulation of neuronal gluta-
mate receptors speciﬁcally sensitive to N-methyl-D-aspartate
(NMDA) producing depolarization (Stone and Perkins, 1981;
Stone, 2001) and excitotoxicity (Schwarcz et al., 1983), while
kynurenic acid is an antagonist at several subtypes of glutamate
receptor (Perkins and Stone, 1982; Stone and Darlington, 2002).
In addition, the pathway includes 3-hydroxykynurenine and
3-hydroxyanthranilic acid, both of which are redox active and
able to produce neuronal damage via the generation of reac-
tive oxygen species (Eastman and Guilarte, 1989, 1990; Okuda
et al., 1996, 1998; Guidetti and Schwarcz, 1999; Giles et al.,
2003). The kynurenine pathway is also an important regulator in
both the innate and adaptive immune response (Gonzalez et al.,
2008).
The ﬁrst and rate limiting enzymes in the kynurenine pathway
are; tryptophan-2,3-dioxygenase (TDO) within the liver, and indo-
leamine-2,3-dioxygenase (IDO), which is widely expressed in a
wide range of cell types including dendritic cells, macrophages,
monocytes, and T-cells in the immune system. The expression of
IDO can be induced by cytokines or the presence of bacterial
lipopolysaccharides leading to a well documented immunosuppres-
sive effect (Gonzalez et al., 2008). The activation of the pathway
by infection, with the generation of neuroactive products, raises
the possibility that it could play a role in the development of the
neuroinﬂammatory response associated with trypanosome infec-
tion and drug treatment. The current study arose out of our inter-
est in identifying novel pathways that might be important in CNS
HAT, and their potential for identifying possible inhibitors to ame-
liorate CNS disease. In this study we have used a highly reproduc-
ible mouse model of early CNS and late CNS stage HAT in
conjunction with Ro-61-8048, a kynurenine-3-monooxygenase
(KMO) inhibitor (Fig. 1), to investigate the effect of manipulating
the production of kynurenine pathway catabolites on the neural
consequences of trypanosome infection.
Materials and Methods
Inhibitor
The high afﬁnity KMO inhibitor 3,4-dimethoxy-N-[4-(3-nitrophenyl)
thiazol-2-yl]benzenesulfonamide (Ro-61-8048; synthesized by
F. Hoffmann-La Roche Ltd.) was dissolved in DMSO and diluted in
sterile 0.9% saline to a concentration of 10mg/ml and the pH
adjusted to 7.5.
Animals, infections and treatments
Female CD1 mice were infected by intraperitoneal injection (i.p.) with
1 10
4 T. b. brucei parasites of cloned stabilate GVR35/C1.9. The
infection was allowed to progress naturally until Day 12 post-infection.
At this point the animals were divided into six groups of six mice.
Groups 1–3 were employed to study the early CNS response while
the late CNS stage was investigated in Groups 4–6. Group 1 was
treated with Ro-61-8048at a dose rate of 100mg/kg (i.p.) every
second day from Day 12 until the end point of the experiment on
Day 28 post-infection. Group 2 was treated at the same time points
1260 | Brain 2009: 132; 1259–1267 J. Rodgers et al.with vehicle (0.9% NaCl–NaOH pH 7.5) only, whereas the infec-
tion was allowed to progress with no intervention in Group 3.
Group 4 mice were given Ro-61-8048 in an identical manner to
Group 1 animals but, on Day 21 post-infection, a time when the
parasites are established within the CNS, the mice were given dimin-
azene aceturate (Berenil; Hoechst) 40mg/kg i.p. This treatment
is subcurative when administered during the CNS stage of the dis-
ease and induces a severe neuroinﬂammatory reaction in the mice.
Group 5 was treated with vehicle and diminazene aceturate
while Group 6 received diminazene aceturate only. Control groups
comprising uninfected inhibitor treated and uninfected inhibitor and
diminazene aceturate treated animals were run in parallel with
the infected groups. A schematic representation of these treatment
regimens is detailed in Fig. 2. Parasitaemia was monitored throughout
the experiment in all infected groups of mice by microscopic exami-
nation of fresh blood smears. At Day 28 post-infection the mice were
killed, the brain excised, ﬁxed in 4% neutral buffered formalin and
parafﬁn wax processed for histological analyses of H&E stained
sections.
All animal procedures were authorized under the Animals (Scientiﬁc
Procedures) Act 1986 and approved by the University of Glasgow
Ethical Review Committee.
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Figure 1 A schematic representation illustrating the main components in the kynurenine pathway of tryptophan metabolism. The
enzymes (italics) and catabolites present along the pathway are shown. Ro-61-8048 inhibits the enzyme KMO (grey highlight).
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The severity of the inﬂammatory reaction in each group of mice was
assessed using a neuropathological grading scale implemented in pre-
vious studies (Kennedy et al., 1997). Brieﬂy, slides were examined by
two independent assessors in a blinded fashion. The severity of the
reaction was graded on a scale of 0 to 4 where 0 represents a normal
brain with no sign of pathological change, Grade 1 shows a mild
meningitis, Grade 2 demonstrates a moderate meningitis with some
degree of perivascular cufﬁng, Grade 3 shows a more severe menin-
gitis with cufﬁng and some inﬁltration of the neuropil by inﬂammatory
cells and Grade 4 is characterized by a severe meningoencephalitis
with the presence of inﬂammatory cells in the brain parenchyma.
In vitro experiments
Bloodstream form T. brucei brucei (strain 427) were cultivated in HMI-9
medium (BioSera Ltd., UK) (Hirumi and Hirumi, 1989) supplemented
with 2mM b-mercaptoethanol (Sigma-Aldrich, UK) and 10% foetal
calf serum (BioSera Ltd., UK) at 37 C in a humidiﬁed 5% CO2 envir-
onment. Trypanotoxicity was determined using an adapted version of
the Alamar Blue assay (Raz et al., 1997). Cells (100mlo f1 10
4 cells/ml)
were added to wells of 96-well plates containing doubling dilutions
of Ro-61-8048 (100ml) ranging in concentration from 50mMt o
12 pM and incubated for 48h. Alamar Blue reagent (20ml, 0.49mM
in PBS, pH 7.4; Sigma-Aldrich, UK) was added to each well. After 24h,
ﬂuorescence was measured using a LS 55 luminescence spectropho-
tometer (PerkinElmer Life and Analytical Sciences, USA) set at excita-
tion and emission wavelengths of 530 and 590nm, respectively. Data
were analysed and IC50 values determined with Prism 5.0 (GraphPad
Software, USA) software. The assay was repeated using a known
trypanocidal drug, pentamidine, to act as a control. The experiment
was performed in duplicate on three independent occasions.
Statistical analyses
Comparisons between groups of animals were carried out to assess the
severity of the neuropathological reaction. The scores were based on
an average of the independent assessor grades measured as described
above. To conﬁrm that the assessors graded the response in a uniform
manner a Wilcoxon signed rank test was employed. Signiﬁcant differ-
ences at the 5% level were detected using ANOVA and Tukey’s mul-
tiple range test. Means, standard errors (SE) and 95% CI’s are given as
summary statistics.
Results
Early CNS stage
In our HAT model, mice infected with T. b. brucei normally survive
to  35 days post-infection without drug intervention. All infected
mice in the groups used to investigate the early CNS reaction
remained parasitaemic throughout the experimental procedure
with trypanosomes demonstrable within the brain sections
(Fig. 3). All animals in the Ro-61-8048 treated group survived
until the end point of the experiment, however, two mice died
before Day 28 post-infection from both the infected untreated
and the infected vehicle treated groups. Analysis of the neuro-
pathology scores (Table 1) from the mice exhibiting the early
CNS stage of the infection showed that treatment with Ro-61-
8048 failed to reduce the neuropathological reaction [mean SE
(1.000 0.214)] signiﬁcantly compared with either the non-trea-
ted (P=0.4445; 1.5 0.204) or the vehicle treated (P=0.773,
1.313 0.344) groups. The uninfected animals showed no patho-
logical changes (0.00 0.00) and this score was signiﬁcantly lower
Group 1 Group 4
D
I > Ro Ro Ro Ro Ro Ro Ro Ro Ro I > Ro Ro Ro Ro Ro Ro Ro Ro Ro
12 14 16 18 20 22 24 26 28 12 14 16 18 20 22 24 26 28
Group 2 Group 5
D
I > VVVVVVVVV I > VVVVVVVVV
12 14 16 18 20 22 24 26 28 12 14 16 18 20 22 24 26 28
Group 3 Group 6
D
I> I>
12 14 16 18 20 22 24 26 28 12 14 16 18 20 22 24 26 28
Group 7 Group 8
D
U > Ro Ro Ro Ro Ro Ro Ro Ro Ro U > Ro Ro Ro Ro Ro Ro Ro Ro Ro
12 14 16 18 20 22 24 26 28 12 14 16 18 20 22 24 26 28
Uninfected control groups
Early CNS-stage groups Late CNS-stage groups
Figure 2 Schematic representation of the treatment regimens used to investigate the effects of Ro-61-8048 (Ro) or vehicle (V)
administration in T. b. brucei infected (I) mice during the early CNS stage of the infection and in animals treated with diminazene
aceturate (D) to induce the late CNS stage of the disease. Uninfected (U) animals were included as controls. The number of days post-
infection is indicated below the regimens. All mice were killed on Day 28 post-infection.
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treated group (P=0.0087, P=0.0211, respectively). This differ-
ence was not reﬂected when the uninfected animals were com-
pared with the infected mice treated with Ro-61-8048
(P=0.0626) (Fig. 4).
Late CNS stage
Parasites were detected in all animals used to investigate the late
CNS stage response prior to administration of trypanocide on
Day 21 post-infection. This treatment is subcurative and although
it clears the trypanosomes from the blood stream parasites within
the CNS are protected from the drug since it cannot cross the
blood–brain barrier efﬁciently (Jennings et al., 1979; Sternberg
et al., 2005). All animals in the infected diminazene aceturate,
Ro-61-8048 treated and the infected diminazene aceturate treated
groups reached the end point in the experiment, however, two
animals died in the infected diminazene aceturate treated group
receiving vehicle.
When the effect of Ro-61-8048 on the development of CNS
inﬂammation in these animals was investigated (Table 2) a
signiﬁcant reduction in the severity of the neuroinﬂammation
(2.792 0.100) was detected compared with infected animals
treated with diminazene aceturate alone (P=0.0284,
3.458 0.187) and those given diminazene aceturate and vehicle
(P=0.0385, 3.500 0.228). All infected groups of animals
showed a signiﬁcantly (P50.000) higher neuropathology score
than that of the uninfected mice treated with Ro-61-8048 and
diminazene aceturate (0.000 0.000) (Fig. 5).
In vitro experiments
In vitro experiments to investigate the effects of Ro-61-8048 on
T. b. brucei (427) showed that addition of the inhibitor to the
culture medium in concentrations ranging from 50mMt o1 2 p M
had no demonstrable effect of trypanosome growth in culture.
When the control, pentamidine, was added to the medium trypa-
nosome growth was rapidly inhibited with the trypanocidal drug
showing an IC50 of 0.2nM and conﬁrming the validity of the
negative result gained from inclusion of the inhibitor (Fig. 6).
Discussion
Inhibition of KMO diverts the kynurenine pathway towards
the production of neuroprotective kynurenic acid and inhibits the
production of catabolites with neurotoxic properties such as
3-hydroxykynurenine, 3-hydroxyanthranilic acid and quinolinic
acid. Manipulation of the pathway in this manner should provide
a more neuroprotective environment, reducing neurotoxicity and
inﬂammation and producing an overall beneﬁcial effect.
We have shown that inhibition of KMO in a murine model of
HAT results in an amelioration of CNS inﬂammation that is highly
dependent on the stage of the infection. When Ro-61-8048 was
administered in mice which had been treated to induce the early
CNS stage of the disease, and which therefore exhibited only a
limited degree of CNS inﬂammation, no reduction in the severity
of the neuroinﬂammatory response was detected. However, when
animals were treated sub-curatively on Day 21 post-infection with
diminazene aceturate to induce pathology mirroring the late CNS
stage of the disease, a signiﬁcant reduction in the CNS inﬂamma-
tory reaction was apparent.
It is well documented that activation of the kynurenine path-
way, speciﬁcally induction of indolamine-2,3-dioxygenase (IDO)
Figure 3 H&E stained section through the vascularized space
situated between the hippocampus and the thalamus adjacent
to the third ventricle, taken from a T. b. brucei infected mouse
killed on Day 28 post-infection following treatment with Ro-
61-8048. Note the presence of high numbers of trypanosomes
(!) throughout the area occupied by the red blood cells.
Table 1 Assessment of the inﬂuence of Ro-61-8048 treatment on the severity of the early CNS stage neuropathological
response
I + Ro I I + V U + Ro
I P=0.4445 ( 0.454, 1.454)
I+V P=0.7731 ( 0.641, 1.266) P=0.9511 ( 1.232, 0.858)
U+R o P=0.0626 ( 2.045, 0.045) P=0.0087 (0.371, 2.629) P=0.0211 (0.184, 2.441)
Mean SE 1.000 0.214 1.500 0.204 1.313 0.344 0.000 0.000
Number 6 4 4 3
The neuropathology scores were measured in mice infected (I) with T. b. brucei and treated with Ro-61-8048 (Ro) or vehicle (V). Uninfected (U), Ro-61-8048 treated
mice were assessed in parallel with the infected animals. The mean score and standard error (Mean SE) together with the number of animals in each group are
detailed. The ﬁgures in the body of the table demonstrate the comparisons, in terms of statistical signiﬁcance, between the groups shown in the row and column
headings. The 95% CIs for the differences between the group means are given along with the P-values.
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this topic has been recently reviewed by Gonzalez et al. (2008). In
brief, the ‘tryptophan depletion theory’ suggests that the upregu-
lation of IDO that occurs in immune cells following stimulation
with IFN- or lipopolysaccharides leads to a depletion of the
essential amino acid tryptophan which is required for protein syn-
thesis and cell division. This lack of tryptophan ‘starves’ any rapidly
dividing pathogens of an essential amino acid consequently inhib-
iting their growth and proliferation. Evidence to support this
theory has been found by many researchers mainly through
in vitro studies. Pfefferkorn (1984) has shown that IFN-
mediated IDO induction leads to reduced tryptophan
concentrations in the culture medium that correlate with inhibition
of Toxoplasma gondii growth (Pfefferkorn, 1984) and a similar
result was found when staphyloccocal infections of vascular
endothelial cell cultures were investigated (Schroten et al.,
2001). However data from animal disease models investigating
either pathogen proliferation or tryptophan levels following infec-
tion are limited. Studies using a murine model of cerebral malaria
suggest that factors other than tryptophan depletion play a role in
CNS protection following IDO induction. These investigations
showed that Plasmodium berghei ANKA infection, strongly
induced IDO expression in the brain leading to reduced trypto-
phan levels. However, it is likely that the reduced tryptophan
Figure 4 Coronal sections through the hippocampal brain region of T. b. brucei-infected mice exhibiting the early CNS stage of the
disease. The animals were treated with Ro-61-8048 (100mg/kg i.p.) (A) untreated animals (B) or vehicle only (C). Uninfected mice
treated with Ro-61-8048 (D) are included as a control. All treatments were administered every second day beginning on Day 12 post-
infection until the end point of the experiment on Day 28 post-infection. Note the presence of mild inﬂammation in sections A–C with
a few inﬂammatory cells present around the blood vessels. No inﬂammatory changes are apparent in the uninfected animals (D).
Table 2 Assessment of the inﬂuence of Ro-61-8048 treatment on the severity of the late CNS stage neuropathological
response
I   D + Ro I   DI   D+V U  D+R o
I–D P=0.0284 (0.062, 1.272)
I–D+V P=0.0385 (0.032, 1.385) P=0.9979 ( 0.635, 0.718)
U   D+R o P50.0001 ( 3.533,  2.051) P50.0001 (2.717, 4.199) P50.0001 (2.700, 4.300)
Mean SE 2.792 0.100 3.458 0.187 3.500 0.228 0.000 0.000
Number 6 6 4 3
The neuropathology scores were measured in mice infected (I) with T. b. brucei and treated with Ro-61-8048 (Ro) or vehicle (V). Uninfected (U), Ro-61-8048 treated
mice were assessed in parallel with the infected animals. All animals were treated with diminazene aceturate (D) on Day 21 post-infection to induce a late-stage
response. The mean score and standard error (Mean SE) together with the number of animals in each group are detailed. The ﬁgures in the body of
the table demonstrate the comparisons, in terms of statistical signiﬁcance, between the groups shown in the row and column headings. The 95% CIs for the differences
between the group means are given along with the P-values.
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when IDO expression was inhibited by dexamethasone treatment,
no concomitant increase in parasitaemia was detected (Sanni
et al., 1998). Furthermore, in vitro studies have shown that
activated immune cells can be selectively inhibited by IDO
catabolites and that this inhibition is enhanced following
tryptophan depletion but not dependent upon it (Frumento
et al., 2002; Terness et al., 2002). Therefore, a second hypothesis,
the ‘tryptophan utilization theory’, was devised which takes into
account the pharmacological actions of kynurenine pathway
metabolites in the control of immune reactions in addition to the
biostatic effect of tryptophan depletion (Moffett and Namboodiri,
2003). Alterations in the generation of tryptophan catabolites by
Ro-61-8048 have been demonstrated previously in a murine
model of cerebral malaria (Clark et al., 2005). Following Ro-61-
8048 treatment dramatic increases in the levels of both kynurenic
acid and anthranilic acid were detected in the brains of both con-
trol mice and animals infected with P. berghei ANKA. Anthranilic
acid (Jhamandas et al., 1990) and kynurenic acid (Perkins and
Stone, 1982; Stone and Darlington, 2002) have both been
shown to act as antagonists to the neurotoxic actions of quinolinic
acid and could thereby reduce the excitotoxicity of endogenous
quinolinic acid or glutamate, resulting in the prolonged survival
found in inhibitor treated P. berghei infected mice.
Figure 6 Trypanosoma brucei (427) bloodstream form
trypanosomes were treated in vitro with Ro-61-8048 (open
circle) or pentamidine control (closed square) and the ﬂuores-
cence emission measured using the Alamar blue test. Ro-61-
8048 appeared to have no inﬂuence on trypanosome growth
and proliferation while pentamidine showed an IC50 of 0.2nM.
Figure 5 Coronal sections through the hippocampal brain region of T. b. brucei-infected mice exhibiting the late CNS stage of the
disease. The animals were treated with Ro-61-8048 (100mg/kg i.p.) (A) untreated animals (B) or vehicle only (C). Uninfected mice
treated with Ro-61-8048 (D) are included as a control. All treatments were administered every second day beginning on Day 12 post-
infection until the end-point of the experiment on Day 28 post-infection. All mice were treated with diminazene aceturate (40mg/kg i.p.)
on Day 21 post-infection to exacerbate the inﬂammatory reaction. Note the reduced numbers of inﬂammatory cells present around the
blood vessels and within the ventricle in infected animals that were treated with Ro-61-8048 (A) compared to animals that were not
given the inhibitor (B, C). No inﬂammatory changes are apparent in the uninfected animals (D).
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show only mild inﬂammatory changes with the presence of a lim-
ited number of T-cells and macrophages in the brain accompanied
by a diffuse astrogliosis whereas late CNS stage mice show higher
numbers of T-cell and macrophages as well as the presence of
B-cells and plasma cells in the inﬂammatory inﬁltrate and a more
pronounced astroglial activation (Jennings et al., 1997). In addi-
tion, lower levels of IFN- are found in the brain of mice during
the early CNS stage of the disease compared with the late CNS
stage animals (Sternberg et al., 2005). When these two factors are
considered in tandem it is possible that manipulation of the kynur-
enine pathway, towards the production of kynurenic acid through
inhibition of KMO, could alter the ratio of quinolinic acid to
kynurenic acid in this HAT model, producing a more favourable
local environment and limiting the severity of the inﬂammatory
neurotoxic reaction. This may be more pronounced in cases
where increased levels of inﬂammation are found since the
higher IFN- levels and abundance of inﬂammatory cells could
result in elevated levels of IDO expression compared with the
early CNS stage of the disease. This widespread activation of
the kynurenine pathway could allow Ro-61-8048 to have a
much greater effect on reducing the production of additional
downstream catabolites, such as 3-hydroxykynurenine, 3-hydroxy-
anthranilic acid and 5-hydroxyanthranilic acid, which increase cell
death (Smith et al., 2007). The overall effect of manipulating the
pathway in this manner would manifest in a reduction in the
neuroinﬂammation found in late CNS stage mice but with only
minimal changes in early CNS stage animals. Vincendeau et al.
(1999) found a striking reduction in tryptophan levels in the
serum of mice following T. b. brucei infection, corresponding
with the number of circulating parasites suggesting that trypano-
somes utilize exogenous sources of tryptophan (Vincendeau et al.,
1999). This was conﬁrmed by in vitro investigations using
T. b. gambiense parasites that demonstrated a depletion of tryp-
tophan in the culture medium correlating with the number of
trypanosomes present (Vincendeau et al., 1999). As the develop-
ment of trypanosomiasis progresses in our model, very mild
inﬂammatory changes in the CNS can be detected on microscopic
examination from Day 14 post-infection with the reaction becom-
ing more pronounced with time but never reaching the severity
seen in sub-curatively treated mice. The numbers of parasites
detected within the CNS also increases in parallel with the devel-
opment of the pathology (author’s unpublished observations). In
this situation, the depletion of tryptophan would reduce the for-
mation of toxic metabolites such as quinolinic acid and 3-hydroxy-
kynurenine, generating a picture of mild inﬂammation without
signiﬁcant neurotoxicity. However, following sub-curative treat-
ment, with diminazene aceturate, to induce the late CNS stage
of the disease the parasitaemia within the brain decreases drama-
tically. This could allow the tryptophan levels to increase, permit-
ting the activation of the kynurenine pathway and generating the
associated cascade of catabolites capable of enhancing the inﬂam-
matory reaction and producing neurotoxicity. Under these circum-
stances, inhibition of KMO could result in the signiﬁcant decrease
in inﬂammation seen following treatment with Ro-61-8048 in our
model.
Trypanosoma brucei has been shown to possess genes encoding
orthologues of enzymes of the kynurenine pathway including a
putative KMO (Accession number XP_827034), although to
date, the enzyme has not been expressed and its function veriﬁed.
Untargeted metabolomic analysis (Kamleh et al., 2008) revealed
the presence of kynurenine in trypanosome extracts indicating that
the parasites do possess a kynurenine pathway. However, in vitro
testing of Ro-61-8048 showed that even at concentrations as high
as 50 mM the drug was inactive against T. brucei bloodstream
form, and early CNS stage mice remained parasitaemic throughout
the Ro-61-8048 administration (Fig. 3). This indicates that the
anti-inﬂammatory response seen following Ro-61-8048 treatment
is due to effects on host cells and not secondary effects involving
parasite destruction.
The evidence gained from this study demonstrates a reduction
of the inﬂammatory reaction within the CNS following inhibition
of KMO in late CNS stage trypanosome infection. This implies that
Ro-61-8048, or a similar inhibitory compound, may be of use as
an adjunct to current trypanocidal therapy in CNS-stage disease to
help prevent and/or ameliorate the devastating PTRE that kills
about 5% of all patients who are treated with melarsoprol.
Further work will be necessary both to extend these ﬁndings
and to unravel the complex biochemical mechanisms underlying
them.
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